抄録
Clinical transplantation requires nonspecific immunosuppressive agents to prevent graft rejection. The use of such agents decrease morbidity and mortality from its associated side effects. Therefore, clinical application of the donor-specific tolerance is needed. We have proposed two transplantation tolerance systems. One is drug-induced tolerance and the other is monoclonal antibody-induced tolerance system. In this article, we reviewed our own donor-specific transplantation tolerance systems and argue its possibility of clinical application.
